X-ray Activable Caged Compounds for Deep Tissue Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering biologically active compounds face challenges in achieving localized and controlled release in deep tissues due to the lack of effective activation by X-ray or gamma-photon irradiation, leading to inefficient targeting and potential side effects.
Innovation Solution
Development of novel caged compounds derived from quinoline derivatives tethered to chelating agents like DOTA and DTPA, which are sensitive to X-ray and gamma-photon activation, allowing for spatiotemporal control of drug release in deep tissues with minimal perturbation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If conventional prodrug strategies are used with enzyme activation, then drug delivery can be achieved, but localized control is lost due to ubiquitous enzyme presence allowing premature activation
Solution Approach 1:
The patent replaces enzyme-based chemical activation with X-ray/gamma-photon irradiation as the activation mechanism. This substitution eliminates the problem of ubiquitous enzyme presence causing premature activation, as radiation can be precisely controlled and delivered only to the target site, achieving both delivery capability and localized control.
Solution Approach 2:
The patent changes the activation parameter from chemical enzyme catalysis to physical radiation energy. By using X-ray or gamma-photon irradiation as the activation trigger, the system achieves precise spatio-temporal control over drug release, as radiation can be applied only when and where needed, overcoming the lack of localized control inherent in enzyme-based systems.
2Manufacturing precision
If UV or IR light is used for photolysis, then spatial control is achieved, but penetration depth is limited to less than 1 mm
Solution Approach 1:
The patent changes the radiation type parameter from UV/IR light to X-ray or gamma-photon. This parameter change enables deep tissue penetration while maintaining spatial control capability, as radiation can be focused and delivered to deep targets without the depth limitations inherent in UV/IR photolysis methods.
Solution Approach 2:
The patent uses X-ray or gamma-photon irradiation as an intermediary energy form that can penetrate deep tissues and activate the caged compound. This intermediary radiation type bridges the gap between achieving deep tissue access and maintaining precise spatial control, overcoming the limitation of conventional photolysis wavelengths.
3Length of stationary object
If X-ray or gamma-photon irradiation is used for activation, then deep tissue penetration is achieved, but no suitable photolabile compounds existed until now
Solution Approach 1:
The patent modifies the molecular structure of photolabile compounds to incorporate moieties that absorb X-ray or gamma-photon energy. This parameter change in compound structure enables activation by deep-penetrating radiation, expanding the versatility of photoactivatable compounds to work with X-ray/gamma-photon sources while maintaining deep tissue penetration capability.
Solution Approach 2:
The patent creates composite molecular structures combining caged compounds with X-ray/gamma-photon absorbing moieties. These composite structures enable simultaneous achievement of deep tissue penetration and photolabile activation, resolving the incompatibility between radiation type and compound suitability by integrating functional elements into a unified molecular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds enable precise and controlled release of biologically active compounds in deep tissues with high sensitivity to X-ray and gamma-photon irradiation, offering selective targeting and minimized side effects, and are stable in physiological media.
Implementation Method 1
The compounds of the invention undergo photolysis by irradiation with X-ray or gamma-photon sources, and transfer a part of the energy absorbed to the quinoline group, which undergoes subsequent fragmentation and liberates the Z-H compound.
Data Source
AI summary
The present invention relates to a X-ray and gamma-photon activable compound responding to the following formula (I). The present invention also relates to methods of synthesizing a compound according to the invention, and to an aqueous or physiological solution comprising at least one compound of the invention. The present invention also concerns a method of liberating a biologically active compound, said method involving the step of irradiating at least one compound, or at least one aqueous or physiological solution according to the invention. Finally, the present invention relates to a pharmaceutical composition comprising at least one compound, or at least one aqueous or physiological solution according to the invention.